Lepton PharmaceuticalsLepton Pharmaceuticals
 
Lepton PharmaceuticalsLepton Pharmaceuticals
  • Home
  • About Us
    • About Us
    • Board of directors
    • Team
  • Our Products
    • Pipeline
    • LN-Cast-01
    • LN-008 si-MASP2
  • Our Science
    • miRNA based Castling
    • siRNA and miRNA
    • Non-coding RNA
    • siRNA Advantages
  • Contact Us
  • News

Recent Posts

  • July 26, 2022ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

  • February 14, 2022Lepton signs Consulting Agreement with Cell Therapy Expert Dr. Elena Sotillo, Senior Research Scientist at the lab of Prof. Crystal Mackall founding director, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, Ca, USA

  • February 4, 2022Prof. Malcolm K Brenner, M.D., Ph.D. Founding Director of Baylor College of Medicine’s Center for Cell and Gene Therapy Houston, TX US agreed to consult to Lepton

  • February 1, 2022Lepton signs Consulting Agreement with Dr. Paz Einat

  • December 2, 2021Lepton announces filing of a PCT application covering its proprietary breakthrough Castling Technology

https://www.leptonpharma.com/wp-content/uploads/2021/04/logo_white_big-160x160.png

© 2021 Lepton Pharmaceuticals Inc.  All rights reserved

Our products

  • LN-Cast-01
  • LN-008 siMASP2

Our science

  • Castling Technology
  • siRNA and miRNA
  • Non-coding RNA
  • siRNA Advantages

Terms of use

  • Terms of Use
  • Copyright Info
  • Privacy Policy